INCB 8696

Drug Profile

INCB 8696

Alternative Names: INCB8696

Latest Information Update: 14 May 2009

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Anti-inflammatories; Neuropsychotherapeutics
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lupus nephritis; Multiple sclerosis

Most Recent Events

  • 31 Dec 2008 Discontinued - Phase-I for Lupus nephritis in USA (PO)
  • 31 Dec 2008 Discontinued - Phase-I for Multiple sclerosis in USA (PO)
  • 31 Dec 2008 INCB 8696 is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top